Literature DB >> 19273791

Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors.

Carol L Shields1, Melis Palamar, Pooja Sharma, Aparna Ramasubramanian, Ann Leahey, Anna T Meadows, Jerry A Shields.   

Abstract

OBJECTIVE: To evaluate retinoblastoma regression patterns following chemoreduction and adjuvant therapy. PARTICIPANTS: A total of 557 retinoblastomas.
METHODS: A retrospective medical record review following 6 cycles of chemoreduction and tumor consolidation (thermotherapy or cryotherapy). Regression patterns included type 0 (no remnant), type 1 (calcified remnant), type 2 (noncalcified remnant), type 3 (partially calcified remnant), and type 4 (flat scar). MAIN OUTCOME MEASURES: Regression pattern.
RESULTS: Retinoblastoma regressions were type 0 (n = 10), type 1 (n = 75), type 2 (n = 28), type 3 (n = 127), and type 4 (n = 317). Tumors with an initial thickness of 3 mm or less regressed most often to type 4 (92%), those 3 to 8 mm regressed to type 3 (34%) or type 4 (40%), and those thicker than 8 mm regressed to type 1 (40%) or type 3 (49%). Factors predictive of type 1 regression included larger tumor base and closer foveolar proximity. Factors predictive of type 3 included older age, larger tumor base, macular location, closer foveolar proximity, and lack of consolidation. Factors predictive of type 4 included familial hereditary pattern, smaller tumor base, greater foveolar distance, and tumor consolidation.
CONCLUSIONS: Following chemoreduction, most small retinoblastomas result in a flat scar, intermediate tumors in a flat or partially calcified remnant, and large tumors in a more completely calcified remnant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273791     DOI: 10.1001/archophthalmol.2008.626

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  20 in total

1.  Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

Authors:  Sofia Theodoropoulou; Paraskevi E Kolovou; Yuki Morizane; Maki Kayama; Fotini Nicolaou; Joan W Miller; Evangelos Gragoudas; Bruce R Ksander; Demetrios G Vavvas
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

Review 2.  Retinoblastoma and vision.

Authors:  Omar Warda; Zishan Naeem; Kelsey A Roelofs; Mandeep S Sagoo; M Ashwin Reddy
Journal:  Eye (Lond)       Date:  2022-01-05       Impact factor: 3.775

3.  Response criteria for intraocular retinoblastoma: RB-RECIST.

Authors:  Jesse L Berry; Francis L Munier; Brenda L Gallie; Ashley Polski; Sona Shah; Carol L Shields; Dan S Gombos; Kathleen Ruchalski; Christina Stathopoulos; Rachana Shah; Rima Jubran; Jonathan W Kim; Prithvi Mruthyunjaya; Brian P Marr; Matthew W Wilson; Rachel C Brennan; Guillermo L Chantada; Murali M Chintagumpala; A Linn Murphree
Journal:  Pediatr Blood Cancer       Date:  2021-02-23       Impact factor: 3.167

4.  Diagnostic image quality of gadolinium-enhanced T1-weighted MRI with and without fat saturation in children with retinoblastoma.

Authors:  Selma Sirin; Marc Schlamann; Klaus A Metz; Norbert Bornfeld; Bernd Schweiger; Markus Holdt; Michael M Schuendeln; Simone Lohbeck; Andrej Krasny; Sophia L Goericke
Journal:  Pediatr Radiol       Date:  2013-01-13

5.  Full-field electroretinography under general anesthesia in retinoblastoma.

Authors:  Ramya Sachidanandam; S Krishnakumar; Lingam Gopal; Joan M O'Brien; Vikas Khetan; Parveen Sen
Journal:  Doc Ophthalmol       Date:  2013-01-04       Impact factor: 2.379

6.  The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.

Authors:  Katarzyna Brodowska; Ahmad Al-Moujahed; Anna Marmalidou; Melissa Meyer Zu Horste; Joanna Cichy; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Exp Eye Res       Date:  2014-05-15       Impact factor: 3.467

7.  Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments.

Authors:  Jae Min Kim; Jeong Hun Kim; Seong-Joon Kim; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn; Young Suk Yu
Journal:  Korean J Ophthalmol       Date:  2010-11-23

8.  Retinoblastoma: Recent trends A mini review based on published literature.

Authors:  Vikas Khetan; Aditi Gupta; Lingam Gopal
Journal:  Oman J Ophthalmol       Date:  2011-09

9.  Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis.

Authors:  Sofia Theodoropoulou; Katarzyna Brodowska; Maki Kayama; Yuki Morizane; Joan W Miller; Evangelos S Gragoudas; Demetrios G Vavvas
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

Review 10.  Conservative treatment modalities in retinoblastoma.

Authors:  Bhavna Chawla; Amit Jain; Rajvardhan Azad
Journal:  Indian J Ophthalmol       Date:  2013-09       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.